Translocation renal cell carcinoma, disproportionately affecting children and young adults, has long eluded effective treatment, partly due to the complexity of its driving genetic alterations. At the heart of this malignancy lie TFE3 oncofusions—recombinant proteins produced from chromosomal rearrangements that forcibly bind together segments of DNA that should remain separate. Understanding how these fusion proteins commandeer the cellular machinery has been a formidable challenge. The Texas A&M team’s research reveals that these oncofusions co-opt RNA molecules not merely as conveyers of genetic instructions but as architects constructing dynamic liquid-like droplets within the cell nucleus. These condensates act as transcriptional hotspots, intensifying the expression of genes that fuel tumor growth.

Contrary to the longstanding view of RNA as merely passive messengers transferring genetic data from DNA to proteins, the study illuminates RNA’s role as an active engineering scaffold within cancer cells. By assembling intricate, phase-separated condensates, RNA creates concentrated environments that aggregate fusion proteins and co-factors into transcriptional hubs. These structures augment the ability of TFE3 oncofusions to activate oncogenic gene expression, effectively transforming the nuclear landscape into a playground for unchecked proliferation. The team’s investigation further identifies PSPC1, an RNA-binding protein, as a formidable stabilizer that reinforces the structural integrity and functionality of these droplets, amplifying their pathological impact.

Elucidating these processes required harnessing a suite of state-of-the-art molecular techniques. CRISPR gene editing allowed precise tagging of the TFE3 oncofusion proteins in patient-derived cell lines, enabling high-resolution tracking of their spatial distribution within the nucleus. The employment of SLAM-seq, a cutting-edge sequencing methodology, provided temporal snapshots of nascent RNA synthesis dynamics, revealing shifts in gene activation patterns coinciding with droplet formation. Complementary approaches such as CUT&Tag and RIP-seq were instrumental in mapping the binding sites of fusion proteins on chromatin and RNA substrates, respectively, delineating the molecular geography of these transcriptional hubs. Proteomics analysis further enriched the picture, pinpointing key protein constituents, most notably PSPC1, that orchestrate condensate stabilization.

While illuminating the mechanism was a monumental achievement, the researchers boldly pressed on to test the vulnerability of these droplets. To translate their insight into therapeutic potential, they engineered a sophisticated chemogenetic system leveraging nanobody technology. Nanobodies, compact antibody fragments, were fused to a specialized dissolver protein designed to selectively dismantle these condensates. Upon chemical activation, the nanobody locks onto the TFE3 fusion proteins, instigating the dispersal of the liquid-like hubs. This molecular switch wielded remarkable efficacy, halting proliferation in cultured cancer cells and significantly curbing tumor growth in mouse models. Such a strategy signals a transformative approach to an aggressive pediatric cancer currently devoid of targeted treatments.

The potential implications of these findings extend well beyond tRCC. Fusion proteins are notorious culprits across various pediatric malignancies, notoriously difficult to target with conventional therapeutics. The discovery of RNA-mediated phase-separated condensates as critical enablers of oncogenic transcription opens a novel frontier for therapeutic intervention. By selectively disrupting these liquid droplet hubs, scientists may be able to dismantle the very platforms that consolidate oncogenic signals, effectively “cutting the power” to the cancer’s growth machinery. This represents a paradigm shift, focusing on the emergent properties of molecular assemblies rather than individual protein targets.

This work underscores the nuanced complexity of cancer cell biology, where the cellular environment and molecular interactions are as vital as the genetic mutations themselves. It challenges the traditional dogma that RNA functions solely as an ephemeral intermediate, exposing its architectural capabilities in pathological states. The strategic targeting of condensate formation Poignantly embodies the promise of precision medicine, aiming to intervene at the molecular nexus of cancer cell survival while minimizing collateral damage to normal tissues. Such precision is crucial in pediatric settings, where long-term side effects of therapy can significantly impact quality of life.

Moreover, the multidisciplinary approach employed by the Texas A&M team exemplifies the power of contemporary biomedical research, fusing gene editing, novel sequencing, chromatin profiling, and proteomic techniques into a cohesive investigative framework. This convergent strategy enabled the researchers to dissect the condensate biology at an unprecedented depth, building a comprehensive model that integrates structural, functional, and therapeutic dimensions. The ability to visualize, mechanistically explore, and then chemically control these RNA-protein assemblies heralds an exciting era of targeted cancer treatments.

The central role of PSPC1 as a droplet stabilizer enriches the mechanistic insights and presents an additional therapeutic target. By modulating proteins that buttress the condensates, future interventions could employ dual strategies—disrupting both scaffold RNA and stabilizer proteins to maximize the collapse of oncogenic hubs. Such combinatorial approaches could enhance the robustness and durability of therapeutic responses, potentially overcoming resistance mechanisms that often plague monotherapies.

Acknowledging the formidable clinical challenge posed by tRCC, which accounts for nearly a third of renal cancers in younger populations, this research represents a beacon of hope. It translates fundamental discoveries into actionable strategies, potentially paving the way for safer and more effective treatments tailored to the unique biology of pediatric cancers. The precision with which these condensates can now be pinpointed and manipulated also invites broader applications in oncology, particularly in cancers where aberrant gene fusions redefine cellular identity and behavior.

The collaborative efforts of molecular biologists, geneticists, structural biologists, and translational researchers at Texas A&M Health highlight the interdisciplinary nature of modern cancer research. Their work not only deciphers the complex “condensate code” exploited by tumors but also charts a blueprint for innovative drug design in an era hungry for breakthroughs beyond traditional chemotherapy and targeted kinase inhibitors. As the field advances, the study’s findings may catalyze the development of condensate-targeting drugs, nanobody therapies, and chemogenetic tools—creating a new arsenal against cancers driven by elusive fusion proteins.

Ultimately, the discovery redefines the conceptual framework of cancer pathogenesis, emphasizing how RNA’s role transcends classical functions and participates actively in the spatial organization of gene regulation. By exposing and then toggling off the molecular switches that sustain cancerous growth hubs, the Texas A&M research not only unravels fundamental biological secrets but lights a path toward transforming clinical outcomes in a devastating, previously intractable disease.

Subject of Research: Translocation renal cell carcinoma (tRCC) and RNA-mediated oncogenic condensates

Article Title: RNA-mediated condensation of TFE3 oncofusions facilitates transcriptional hub formation to promote translocation renal cell carcinoma

News Publication Date: 30-Sep-2025

Web References:

• Texas A&M Health: https://health.tamu.edu/
• Original Study DOI: http://dx.doi.org/10.1038/s41467-025-63761-z

References:

• Study published in Nature Communications, DOI 10.1038/s41467-025-63761-z

Keywords:
Cancer research, Tumor microenvironments, Cancer cells, Oncology, Signal transduction, Extracellular spaces, Cancer treatments, Biomedical engineering, Diseases and disorders, Health and medicine, Translational research, Clinical medicine, Drug delivery systems

At the heart of this discovery lies the phenomenon of liquid-liquid phase separation, a biophysical process increasingly recognized as fundamental to cellular organization. The researchers demonstrated that unlike the normal TFE3 protein, which diffusely distributes throughout the cell nucleus, the aberrant TFE3 fusion proteins coalesce into dense, droplet-like condensates adjacent to DNA. These condensates function as dynamic hubs that recruit co-regulatory proteins and chromatin remodeling factors, effectively rewiring the epigenetic landscape to favor the transcriptional activation of genes that promote tumor growth and metastasis.

The team specifically focused on two of the most prevalent TFE3 fusion variants involving NONO and SFPQ gene partners, which collectively represent approximately 40% of all TFE3 rearrangements seen in tRCC patients. By tagging these fusion proteins with fluorescent markers and visualizing them in live patient-derived cancer cells, the scientists observed the temporal dynamics of droplet formation and dissolution. Crucially, these condensates were found to sequester both histone modification enzymes and transcriptional activators, indicating a direct mechanistic link between condensate assembly and chromatin accessibility.

Chromatin, the highly organized structure of DNA and proteins within the nucleus, regulates gene expression by modulating the exposure of DNA sequences to the transcriptional machinery. In the chromatin “beads-on-a-string” model, tightly wrapped DNA around nucleosomes corresponds to gene repression, while relaxed or open chromatin permits gene activation. The TFE3 fusion condensates appear to manipulate this structural equilibrium, chemically modifying histone tails to promote the opening of chromatin at specific loci. This epigenomic reprogramming facilitates the upregulation of genes that enhance cellular proliferation and motility, key hallmarks of cancer invasiveness.

Collaborating closely, co-investigator Eneda Toska, Ph.D., an assistant professor of oncology, provided essential insights into the fusion proteins’ interaction with chromatin. Her team utilized advanced assays to map genome-wide changes in chromatin accessibility and found distinct patterns of gain and loss at enhancer and promoter regions targeted by the TFE3 fusions. This targeted rewiring of the chromatin landscape suggests that fusion protein condensates act as master regulators, selectively activating oncogenic pathways while potentially repressing tumor-suppressive genes.

Intriguingly, the structural integrity of these nuclear condensates was shown to depend on a specialized domain within the fusion proteins forming a coiled-coil motif—an alpha-helical structure that mediates protein-protein interactions. Deletion or mutation of this segment disrupted condensate formation, abrogated the fusion proteins’ ability to induce chromatin remodeling, and, importantly, negated the activation of cancer-driving genes. These findings underscore the pivotal role of phase separation-mediated condensate assembly in the oncogenic function of TFE3 fusion proteins and suggest potential therapeutic targets.

The implications of these results extend beyond tRCC, as fusion genes and protein condensates are increasingly implicated in a variety of cancers. Senior author Danfeng “Dani” Cai, Ph.D., posits that other fusion gene-driven malignancies such as Ewing sarcoma and certain leukemias may employ analogous mechanisms involving liquid-liquid phase separation to regulate gene expression. Understanding these biophysical underpinnings opens a promising avenue for developing treatments that specifically disrupt aberrant condensate formation, thereby silencing cancer-promoting gene networks without broadly affecting normal cellular functions.

Currently, there are no standard treatments for translocation renal cell carcinoma, rendering these mechanistic insights particularly critical. Disrupting the formation or stability of TFE3 fusion condensates could represent a novel therapeutic strategy. The research team envisions future drug discovery efforts focused on identifying small molecules capable of interfering with condensate assembly or destabilizing the protein interactions that sustain these oncogenic droplets. Such targeted approaches would offer precision medicine options for patients with this rare but aggressive kidney cancer subtype.

This study not only reveals fundamental aspects of cancer biology but also exemplifies the growing importance of interdisciplinary approaches combining molecular biology, biochemistry, structural biology, and epigenetics. The researchers employed state-of-the-art imaging techniques, genome-wide chromatin profiling, and protein engineering to dissect the complex interplay between gene rearrangements and nuclear organization. Their integrative methodology sets a new standard for investigating the consequences of fusion gene events in cancer.

The discovery that fusion protein-driven condensates act as epigenetic architects advancing tumorigenesis adds to the expanding paradigm in which membraneless organelles govern key regulatory processes within cells. These dynamic condensates enable spatial and temporal control over gene activation, a feature that cancer cells exploit to gain proliferative and invasive advantages. Targeting such condensates offers a disruptive innovation in cancer therapeutics, moving beyond traditional enzyme inhibition to the modulation of higher-order protein assemblies.

As the research community continues to unravel the biophysical and molecular signatures of fusion oncoproteins in tRCC and beyond, this work lays a critical foundation for translating basic science into clinical interventions. The collaboration among Johns Hopkins teams, supported by various grants including from the National Institutes of Health and the Department of Defense, illustrates the power of concerted efforts to tackle rare but formidable cancers through precise mechanistic understanding.

In summary, the identification of liquid droplets formed by TFE3 fusion proteins and their role in reprogramming chromatin accessibility provides an unprecedented glimpse into the molecular drivers of translocation renal cell carcinoma. This insight paves the way for innovative therapeutic paradigms aiming to dismantle oncogenic condensates, offering new hope to patients facing cancers currently lacking effective treatment options. As cancer biology embraces the complexity of nuclear condensates, the convergence of molecular detail and clinical urgency heralds a transformative era in precision oncology.

—

Subject of Research: Molecular mechanisms of TFE3 fusion proteins in translocation renal cell carcinoma and their role in cancer progression through phase-separated nuclear condensates.

Article Title: Fusion Protein Condensates Drive Oncogenic Chromatin Remodeling in Rare Kidney Cancer

News Publication Date: April 22, 2025

Web References: https://www.cell.com/cell-reports/fulltext/S2211-1247(25)00310-9

References: So, Lee, Vokshi et al., 2025 Cell Reports 44, 115539

Image Credits: So, Lee, Vokshi et al., 2025 Cell Reports 44, 115539

Keywords: Kidney cancer, translocation renal cell carcinoma, fusion proteins, TFE3, liquid condensates, chromatin remodeling, cancer epigenetics, phase separation, oncology, gene regulation